COMMUNIQUÉS West-GlobeNewswire

Amphista Therapeutics to present novel mechanism of action for the degradation of BRD9 using its proprietary Targeted Glue® technology at two key upcoming scientific conferences
20/03/2025
Amphista Therapeutics to present novel mechanism of action for the degradation of BRD9 using its proprietary Targeted Glue® technology at two key upcoming scientific conferences Oral presentations will detail the rapid [...]
Impacts to Paramedic Services Amid Tariff Disputes
20/03/2025
OTTAWA, Ontario, March 20, 2025 (GLOBE NEWSWIRE) -- The Paramedic Chiefs of Canada (PCC) are calling on the federal government to immediately exempt ambulances and their key life-saving medical equipment from the [...]
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
20/03/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Paul Rutherford Carter and [...]
NTG Nordic Transport Group acquires DTK
20/03/2025
Company announcement no. 5 – 25 20 March 2025 NTG Nordic Transport Group acquires DTK NTG Nordic Transport Group A/S (“NTG”) has signed an agreement to acquire 100% of the shares in Danish-based DTK BE Holding ApS (“DTK [...]
Northern Karelia Cooperative Society (PKO) has chosen Aino’s SaaS platform
20/03/2025
Northern Karelia Cooperative Society (PKO), a customer members owned cooperative, has chosen the Aino SaaS platform as part of an initiative to enhance workforce well-being and improve work ability management. PKO [...]
Notice convening the Annual General Meeting in BioPorto A/S
20/03/2025
20 March 2025 Announcement no. 7 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on [...]
BioPorto announces the Annual Report for 2024
20/03/2025
March 20, 2025 Announcement no. 06 BioPorto announces the Annual Report for 2024 Copenhagen, Denmark, March 20, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or company) (CPH:BIOPOR), an in vitro diagnostics company [...]
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
20/03/2025
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB’s (“Xbrane”) R [...]
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
20/03/2025
REYKJAVIK, Iceland and STOCKHOLM, March 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
20/03/2025
Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes [...]
IBA reports solid Full Year 2024 results
20/03/2025
Read the entire full year 2024 results press release here Louvain-la-Neuve, Belgium, 20 March 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated [...]
IBA publie des résultats solides pour l'année 2024
20/03/2025
Cliquez ici pour lire l'intégralité du communiqué de presse des résultats de l'exercice 2024 Louvain-La-Neuve, Belgique, jeudi 20 mars 2025 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’ [...]
Press release: Sequana Medical to Sponsor Liver Connect, 5th Annual Conference of Chronic Liver Disease Foundation
20/03/2025
Sequana Medical to Sponsor Liver Connect, 5 th Annual Conference of Chronic Liver Disease Foundation Ghent, Belgium – 20 March 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical") , a [...]
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
20/03/2025
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition [...]
Communiqué de presse : Sanofi va acquérir l’anticorps bispécifique de Dren Bio – un « engageur » des cellules myéloïdes pour la déplétion profonde des lymphocytes B –, et étoffe son portefeuille en immunologie
20/03/2025
Sanofi va acquérir l’anticorps bispécifique de Dren Bio – un « engageur » des cellules myéloïdes pour la déplétion profonde des lymphocytes B –, et étoffe son portefeuille en immunologie L’agent de déplétion profonde [...]
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
20/03/2025
Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023) Strong year-end cash position of €168.3 million including sale of Priority Review Voucher 1 , successful private placement and [...]
Valneva publie ses résultats financiers 2024 et fait un point sur son activité et ses perspectives financières
20/03/2025
Atteinte des objectifs 2024 de croissance des ventes (+13% vs 2023) et de chiffre d’affaires (+10% vs 2023) Solide position de trésorerie de 168,3 millions d’euros à fin 2024 incluant les produits de la vente du bon de [...]
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
20/03/2025
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today [...]
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
20/03/2025
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of [...]

Pages